Neuropsychiatric Systemic Lupus Erythematosus
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Neuropsychiatric systemic lupus erythematosus (NPSLE) is the least understood, yet perhaps the most prevalent manifestation of lupus. The pathogenesis of NPSLE is multifactorial and involves various inflammatory cytokines, autoantibodies, and immune complexes resulting in vasculopathic, cytotoxic and autoantibody-mediated neuronal injury. The management of NPSLE is multimodal and has not been subjected to rigorous study. Different treatment regimens include nonsteroidal anti-inflammatory drugs, anticoagulation, and immunosuppressives such as cyclophosphamide, azathioprine, mycophenolate mofetil, and methotrexate. For refractory NPSLE, intravenous immunoglobulin (IVIG), plasmapheresis, and rituximab have been used. Adjunctive symptomatic treatment complements these therapies by targeting mood disorders, psychosis, cognitive impairment, seizures or headaches. Several new biological agents are being tested including Belimumab, a human monoclonal antibody that targets B lymphocyte stimulator. This review focuses on the pathophysiology, treatment, and new potential therapies for neuropsychiatric manifestations of systemic lupus erythematosus. Keywords: SLE, neuropsychiatric lupus, immunosuppression, autoimmunity, autoantibody, neuropsychiatric lupus,, inflammatory cytokines, anticoagulation, lymphocyte stimulator, autoimmune disease, systemic lupus erythematosus (SLE), Neuropsychiatric lupus (NPSLE)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cervera, R., Khamashta, M. A., Font, J., Sebastiani, G. D., Gil, A., Lavilla, P., Mejía, J. C., Aydintug, A. O., Chwalinska-Sadowska, H., de Ramón, E., et al. (2003) · Medicine · doi:10.1097/01.md.0000091181.93122.55 · Cited by 1,377
Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients
Shah, N. M., Khamashta, M. A., Atsumi, T., & Hughes, G. R. (1998) · Lupus · doi:10.1191/096120398678919624 · Cited by 204
DANOWSKI, A., de AZEVEDO, M. N. L., de SOUZA PAPI, J. A., & PETRI, M. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.081194 · Cited by 192 · cited 1×
“Moreover, approximately 25% to 40% of lupus patients have secondary antiphospholipid syndrome with clinical features of repeated episodes of arterial or venous thrombosis, recurrent spontaneous abortions, or thrombocytopenia in patients with antiphospholipid (aPL) antibodies [41-45].”
BackgroundAiniala, H., Dastidar, P., Loukkola, J., Lehtimäki, T., Korpela, M., Peltola, J., & Hietaharju, A. (2005) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740510026643 · Cited by 149
Cited by
Lisnevskaia, L., Murphy, G., & Isenberg, D. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60128-8 · Cited by 752
Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers
Jeltsch-David, H., & Muller, S. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.148 · Cited by 304
Microglia-dependent synapse loss in type I interferon-mediated lupus
Bialas, A. R., Presumey, J., Das, A., van der Poel, C. E., Lapchak, P. H., Mesin, L., Victora, G., Tsokos, G. C., Mawrin, C., Herbst, R., et al. (2017) · Nature · doi:10.1038/nature22821 · Cited by 197
RetractedMongan, D., Ramesar, M., Föcking, M., Cannon, M., & Cotter, D. (2020) · Early Intervention in Psychiatry · doi:10.1111/eip.12859 · Cited by 123
Metadata
- Authors
- Popescu, A., & H. Kao, A.
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-09-01
- Volume
- 9
- Issue
- 3
- Pages
- 449-457
- ISSN
- 1570-159X (ISSN-L)
- OpenAlex
- W1974552427
- Cited by
- 200
- References
- 4
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.